NASDAQ:ARVNArvinas Stock Price, Forecast & News

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARVN stock has decreased by 24.6% and is now trading at $33.22. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arvinas.

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Arvinas.

Arvinas Inc (NASDAQ:ARVN) announced its quarterly earnings data on Tuesday, April, 28th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.01. The firm had revenue of $6.24 million for the quarter, compared to the consensus estimate of $5.18 million. Arvinas had a negative return on equity of 30.74% and a negative net margin of 171.74%. View Arvinas' earnings history.

11 analysts have issued 12-month price targets for Arvinas' shares. Their forecasts range from $38.00 to $75.00. On average, they anticipate Arvinas' stock price to reach $57.10 in the next twelve months. This suggests a possible upside of 71.9% from the stock's current price. View analysts' price targets for Arvinas.

Headlines about ARVN stock have been trending extremely negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arvinas earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the near future. View the latest news about Arvinas.

Arvinas saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 3,300,000 shares, an increase of 13.8% from the June 15th total of 2,900,000 shares. Based on an average trading volume of 608,400 shares, the days-to-cover ratio is presently 5.4 days. Currently, 12.9% of the shares of the company are sold short. View Arvinas' Current Options Chain.

Some companies that are related to Arvinas include United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Emergent Biosolutions (EBS), Zai Lab (ZLAB), Legend Biotech (LEGN), Arrowhead Pharmaceuticals (ARWR), Myokardia (MYOK), Blueprint Medicines (BPMC), GW Pharmaceuticals PLC- (GWPH), Global Blood Therapeutics (GBT), Biohaven Pharmaceutical (BHVN), Nektar Therapeutics (NKTR) and Evotec (EVTCY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), ImmunoGen (IMGN), Krystal Biotech (KRYS), Protalix Biotherapeutics (PLX), Senseonics (SENS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Vaxart (VXRT).

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Endurance Wealth Management Inc. (0.01%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, John G Houston, Liam Ratcliffe, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am. View institutional ownership trends for Arvinas.

ARVN stock was purchased by a variety of institutional investors in the last quarter, including Endurance Wealth Management Inc.. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, and Timothy M Shannon. View insider buying and selling activity for Arvinas.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARVN stock can currently be purchased for approximately $33.22.

Arvinas has a market capitalization of $1.30 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]